Companies Maze Therapeutics, Inc.
Maze Therapeutics (MAZE): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me Maze Therapeutics, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $3,458,267FY2025
CEO total pay was $3,458,267 in fiscal 2025; the brief holds no earlier figure for this CEO.
FY2025: salary $629,167 · bonus $0 · stock awards $2,367,000 · option awards $0
Order MAZE
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Misbah Tahir | $164,773 | $50,000 | $0 | $3,659,110 | $86,667 | $0 | $3,500 | $3,964,050 |
| Chief Financial Officer | ||||||||
| Jason Coloma | 629,167 | 0 | 2,367,000 | 0 | 457,600 | 0 | 4,500 | 3,458,267 |
| Chief Executive Officer | ||||||||
| Harold Bernstein | 548,333 | 0 | 946,800 | 0 | 321,750 | 0 | 4,500 | 1,821,383 |
| President, Research and Development and Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Misbah Tahir | $3,964,050 | — | — | — |
| Jason Coloma | 3,458,267 | — | — | — |
| Harold Bernstein | 1,821,383 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jason Coloma | Option | 3,888 | 10.42 | — |
| Harold Bernstein | Option | 14,583 | 10.42 | — |
| Jason Coloma | Option | 25,278 | 10.42 | — |
| Harold Bernstein | RSU | 40,000 | — | 1,657,200 |
| Jason Coloma | Option | 45,498 | 10.42 | — |
| Harold Bernstein | Option | 80,705 | 10.42 | — |
| Jason Coloma | RSU | 100,000 | — | 4,143,000 |
| Harold Bernstein | Option | 106,576 | 10.42 | — |
| Misbah Tahir | Option | 325,000 | 15.32 | — |
| Jason Coloma | Option | 361,033 | 10.42 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Hervé HoppenotIndependent · Board Chair · Audit · Nominating and Corporate Governance | $17,038 | — | $721,688 | — | $0 | $738,726 |
| Charles Homcy, M.DNot independent · Nominating and Corporate Governance · Research and Development | 67,158 | — | 294,907 | — | 240,000 | 602,065 |
| Neil ExterIndependent · Audit · Not standing for re-election | 43,542 | — | 445,132 | — | 0 | 488,674 |
| Richard Scheller, Ph.DIndependent · Research and Development (Chair) | 51,000 | — | 294,907 | — | 60,000 | 405,907 |
| Sekar KathiresanIndependent | 43,962 | — | 320,716 | — | 0 | 364,678 |
| Daniel SpiegelmanIndependent · Audit (Chair) · Nominating and Corporate Governance · Compensation | 54,076 | — | 294,907 | — | 0 | 348,983 |
| Nancy C. Andrews, M.D., Ph.DIndependent · Compensation · Research and Development | 50,583 | — | 294,907 | — | 0 | 345,490 |
| Jonathan Lim, M.DIndependent · Compensation (Chair) | 49,333 | — | 294,907 | — | 0 | 344,240 |
| Catherine Angell Sohn, Pharm.DIndependent · Nominating and Corporate Governance · Not standing for re-election | 48,750 | — | 294,907 | — | 0 | 343,657 |
| Jason Coloma, Ph.DEmployee director | — | — | — | — | — | 0 |
| Neil Kumar, Ph.DIndependent · Audit · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Jeffrey TongIndependent | 0 | — | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $750,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $425,442 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $300,000 |
| Total cost of the board | $725,442 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Maze Therapeutics as a peer
Companies that benchmark against MAZE
No companies currently name MAZE as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Maze Therapeutics, Inc. | 2025 | Jason Coloma | $629,167 | $2,367,000 | $0 | $457,600 | $3,458,267 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-08 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-08 | —a |
a. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (18 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Misbah Tahir. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 3,964,050. View filing ↗
- Section 01, Jason Coloma. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 3,458,267. View filing ↗
- Section 01, Harold Bernstein. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 1,821,383. View filing ↗
- Section 08, Hervé Hoppenot. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 738,726. View filing ↗
- Section 08, Charles Homcy, M.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 602,065. View filing ↗
- Section 08, Neil Exter. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 488,674. View filing ↗
- Section 08, Richard Scheller, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 405,907. View filing ↗
- Section 08, Sekar Kathiresan. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 364,678. View filing ↗
- Section 08, Daniel Spiegelman. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 348,983. View filing ↗
- Section 08, Nancy C. Andrews, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 345,490. View filing ↗
- Section 08, Jonathan Lim, M.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 344,240. View filing ↗
- Section 08, Catherine Angell Sohn, Pharm.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 343,657. View filing ↗
- Section 08, Jason Coloma, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Neil Kumar, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Jeffrey Tong. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-10. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 09b board cost (computed). Computed. Cash 425,442 + equity 0 + all other 300,000 = 725,442, summed across the director compensation table rows.
- Maze Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Maze Therapeutics, Inc.'s own proxy. As printed: 3,458,267. View filing ↗